Guoyuan International: Essex Bio-Technology Embarks on Global Expansion, Maintains BUY Rating with Target Price of HK$6.84
HONG KONG, Apr 8, 2026 – (ACN Newswire via SeaPRwire.com) – Guoyuan International issued a research report on Essex Bio-Technology on 1 April 2026. Essex posted steady operating performance growth in 2025 and kicked off its international expansion, as the Phase III clinical trial of bevacizumab met its primary endpoint and Beifushu® was successfully introduced to Singapore. The global commercialisation of innovative drugs is expected to drive the company’s earnings growth. The institution maintains a BUY rating on the Company with a target price of HK$6.84, representing 84.9% upside from the current price.Essex Bio-Technology’s core R&D pipeline has secured a series of critical milestones. The global phase 3 clinical project of bevacizumab ophthalmic injection (AURA2) has completed the last patient last visit in Australia, European Union countries and the United States, with data analysis now in progress. A Biologics License Application (BLA) for anti-VEGF ophthalmic injection EB12-20145P …

















